Phase 1/1b Study to Evaluate the Safety & PK of JNJ-73841937 a Third Generation EGFR-TKI as Monotherapy or in Combinations With JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced NSCLC

Go Back to All Clinical Trials

Phase 1/1b Study to Evaluate the Safety & PK of JNJ-73841937 a Third Generation EGFR-TKI as Monotherapy or in Combinations With JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced NSCLC

Brief description of study

The purpose of the study is to determine the safety and tolerability of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer. We want to know how the drugs work and what is the best combination dose for the treatment of Non-Small Cell Lung Cancer.

Clinical Study Identifier: s20-00901

ClinicalTrials.gov Identifier: NCT04077463

Principal Investigator: Joshua K Sabari.

Other Investigators: Samantha VanMaanen, Salman Rafi Punekar, Jessica Wang, Elaine Shum, Carol M Lee, Jonathan B Kahn, Gabrielle Fridman, David Mendoza, Natalia Cherkassky, Vamsidhar Velcheti, Avital Benson, Sally Lau, Melissa L Martinez.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies